Pancreatic Tumor Patients Face Later Metastasis Risk

A 208-patient retrospective study presented at the 2026 NANETS symposium tracked how often pancreatic neuroendocrine tumor patients develop metastases after surgery.

Updated on Nov. 5, 2026 in Cancer

Bold flat-color editorial illustration of pale amber cells beside a liver-shaped silhouette linked by a thin rust thread, on a cream field. — Nearly 20% of pancreatic neuroendocrine tumor patients without visible metastases at surgery developed metastatic disease within four years, a 208-patient study presented at NANETS 2026 found. AI Illustration. Upload story photo >

Researchers presented a retrospective study of 208 patients with pancreatic neuroendocrine tumors at the 2026 NANETS symposium. Nearly 20% of patients without metastases at surgery developed metastatic disease within 4 years after resection.

Why it matters

The findings suggest that patients who appear cancer-free after surgery may still face a meaningful risk of metastasis years later, which bears on how long follow-up monitoring should continue. The data come from a single institution, so broader applicability remains to be tested.

The analysis drew on a single-institution database of 208 patients treated from 2000 to 2024, with 18.7% of initially non-metastatic patients developing metastases over a 65-month median follow-up. Because the study is retrospective and limited to one center, it cannot establish how these rates apply to patients elsewhere.

The players

NANETS

The North American Neuroendocrine Tumor Society is a professional organization focused on research and clinical care for neuroendocrine tumors.

The details

Among patients who had metastases when first presenting, liver involvement was found in 95.3% of cases. Among the non-metastatic patients who later developed disease, the median time to metastasis after surgery was 42 months, and liver metastases appeared in 82.6% of those cases.

2000-2024: Patient data collected in the single-institution database.
42 months after resection: Median time to metastasis for patients who later developed disease.
65 months: Median follow-up period for the study cohort.
November 5-7, 2026: NANETS 2026 symposium in Las Vegas, where the study was presented.

Health Landscape

Pancreatic neuroendocrine tumors are a rare category of cancer, and long-term follow-up data remain limited compared with more common tumor types. This retrospective analysis adds to a relatively small body of evidence on how late recurrence and metastasis unfold after surgical resection.

For patients who have had surgery for a pancreatic neuroendocrine tumor, the findings underscore the value of continued surveillance after the initial operation. Patients and clinicians may want to discuss the timing and frequency of follow-up imaging in light of these metastasis rates.

The takeaway

Patients with a history of pancreatic neuroendocrine tumors should keep up with scheduled follow-up care, since metastasis can appear several years after surgery even when initial results look clear. Questions about individual monitoring plans are best directed to a treating oncologist.